SciELO - Scientific Electronic Library Online

 
vol.105 número2Una técnica endoscópica en el tratamiento de la obstrucción sintomática del yeyuno distal dejando en su lugar el sobretuboBiopsia hepática percutánea índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Revista Española de Enfermedades Digestivas

versión impresa ISSN 1130-0108

Rev. esp. enferm. dig. vol.105 no.2 Madrid feb. 2013

http://dx.doi.org/10.4321/S1130-01082013000200010 

CLINICAL NOTE

 

Cholangitis and multiple liver abscesses after percutaneous ethanol injection (PEI) for recurrent hepatocellular carcinoma (HCC)

Colangitis y abscesos hepáticos múltiples tras la inyección percutánea de etanol (IPE) en el tratamiento del carcinoma hepatocelular recurrente

 

 

Fernando Macias-García1,3, Nicolau Vallejo-Senra1,3, Sandra Baleato-González2, Javier Fernández-Castroagudín1,3, Esther Molina-Pérez1,3 and J. Enrique Domínguez-Muñoz1,3

1Gastroenterology and 2Radiology Departments. University Hospital of Santiago de Compostela. Santiago de Compostela. A Coruña, Spain.
3Foundation for Research in Digestive Diseases (FIENAD). Spain

Correspondence

 

 


ABSTRACT

Percutaneous ablation procedures are minimally invasive treatments for unresectable early stage hepatocellular carcinoma (HCC). These techniques are usually safe, but rare and even fatal complications have been described. We present a fatal result after percutaneous ethanol injection (PEI) for the treatment of a recurrent HCC in a non-cirrhotic liver, with subsequent development of diffuse cholangitis and multiple liver abscesses. Although percutaneous drainage and intensive antibiotic treatment were employed, the patient finally died. We discuss about the etiology and the physiopathology of this rare complication in which the therapeutic options are limited and usually unsuccessful.

Key words: Liver. Hepatocellular carcinoma (HCC). Percutaneous ethanol injection (PEI). Ablative percutaneous therapy. Cholangitis.


 

Introduction

Percutaneous ablation procedures (radiofrequency and ethanol injection) are effective and minimally invasive treatments for unresectable early stage hepatocellular carcinoma (HCC). Safety profile of ablation procedures is excellent (1). Nevertheless, major complications, even with fatal course, may occur. In this setting, post-ablation infections such as cholangitis and liver abscess are rare but potentially severe complications (2). It has been previously estimated that an infectious complication could be present up to 1.5 % of PEI sessions (3).

 

Case report

We report the case of a 76-year-old male, with a past history of ischemic arterial coronary, peripheral, and carotid disease, which underwent surgery for coronary by-pass, apendicectomy, and partial gastrectomy with Billroth II type gastroenteroanastomosis because of a perforated duodenal ulcer. At 1995, he was diagnosed of a 36 mm in diameter single HCC at segment VI in a non-cirrhotic liver, and segmentectomy was performed. Four years later, the patient underwent further surgery (right hepatectomy) because of 50 mm in diameter single HCC recurrence. After 10 years of follow-up, two nodules less than 30 mm in diameter at segments III and IV, with typical dynamic HCC pattern in magnetic resonance imaging (MRI), were detected. Percutaneous radiofrequency ablation of the lesion localized at segment IV, and percutaneous ethanol injection (PEI) of the subcapsular nodule localized at segment III were made without complications. Contrast-enhanced computed tomography (CT) four weeks after ablation showed great areas of necrosis in both lesions, but viable neoplastic tissue remained. Two additional cycles of PEI were performed, but no complete response was achieved.

A few days after the third session of the last cycle of PEI, the patient was admitted at hospital because of fever, jaundice and right upper quadrant abdominal pain. Laboratory tests revealed the presence of increased levels of transaminases, cholestasis, and moderate hyperbilirubinemia (total bilirubin 8.4 mg/dL, conjugated bilirubin 6.3 mg/dL, AST 138 UI/L, ALT 213 UI/L, GGT 486 UI/L, alkaline phosphatases 1,082 UI/L), elevated white blood cells count (16,850/µL), elevation of C-reactive protein (11.3 mg/dL), and procalcitonin (2.7 ng/mL). Abdominal contrast-enhanced CT showed a diffuse alteration of the bile ducts compatible with cholangitis, and the presence of several focal liver lesions suggestive of abscesses (Fig. 1A). These findings were confirmed by a liver MRI, which also showed tumor viability of the HCC located at segment IV (Fig. 1B). Magnetic resonance cholangiography excluded the presence of any stenosis in the main bile duct (Fig. 2). Empirical antibiotic therapy was prescribed, which was subsequently modified according to the isolation of Enterobacter cloacae in blood cultures. Ultrasound-guided percutaneous aspiration of fluid of the two larger abscesses was performed. The microbiological culture of these samples was negative.

 

Initial clinical and analytical improvement was observed, but complete resolution of the abscesses was not achieved, and jaundice remained. During the outpatient follow-up, progressive deterioration of the performance status occurred subsequently to recurrence of the cholangitis and the persistence of residual liver abscesses, despite maintenance of the antibiotic treatment. Finally, the patient died 4 months after the ablation procedure.

 

Discussion

HCC occurs mainly in the context of liver cirrhosis, but it may arise in non-cirrhotic liver in 15-20 % of cases (4). Despite the possibility of application of more aggressive treatment in these patients, the overall and disease-free survival are impaired by a high rate of recurrence (5).

Patients with early stage HCC who are not candidates for surgical treatment or liver transplantation must be evaluated for ablative percutaneous therapy. The most frequent complications of PEI are abdominal pain and self-limited fever (6). Although infrequent, major complications, including intraperitoneal hemorrhage, hemobilia, right pleural effusion, portal thrombosis, liver infarction, arterio-portal shunt, pneumothorax, perforation of abdominal organs, neoplastic seeding and shock, have been previously reported (7-10). Infectious complications are rare but potentially severe complications (2), with an estimated incidence up to 1.5 % of PEI sessions (3). Although these infectious complications may be fatal, most of patients recover with antibiotic therapy alone or in combination with percutaneous drainage. Given the fact that the majority of HCC occur on cirrhotic livers the development of the complication reported here could be even more unexpected.

Previous studies have shown that the presence of any biliary abnormality may predispose to infectious complications after percutaneous ablation (2,11). In this setting, the presence of a bilioenteric anastomosis has been strongly correlated with the development of cholangitis and/or liver abscess after PEI (3). In our case, we believe that the morphological changes caused by the previous liver resection surgery may have played a role in the occurrence of post-procedure infectious complication. No other alteration in the bile ducts was observed by the magnetic resonance cholangiography in our case.

The physiopathology of abscess development after PEI is not clearly established. Bacterial contamination of ablated necrotic lesions leading to abscess formation is one of the suspected hypothesis. The bacteria can be inoculated from the outside during the percutaneous ablative procedure, but the enteric bacterial translocation seems to be more frequent (i.e., Escherichia coli, Enterococcus spp, Enterobacter cloacae). Direct damage induced by ethanol on the bile duct can also cause chemical cholangitis, which subsequently leads to the formation of the liver abscesses. In the presented case the precipitating factor could be the development of diffuse chemical cholangitis caused by ethanol, or ischemic injury secondary to direct injection into a left hepatic artery branch, with subsequent enteric bacterial translocation to the necrotic tissue that led to the abscess formation. In this setting, several studies have provided conflicting results regarding to antibiotic prophylaxis previously to perform percutaneous ablative therapies (12). Nowadays, prophylactic administration of antibiotics previously or following a percutaneous ablation procedure seems to have not a significant impact on the post-ablation efficacy or on incidence of infectious complications (13).

 

References

1. Bruix J, Sherman, M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-36.         [ Links ]

2. Shibata T, Yamamoto N, Ikai I, Shimahara Y, Yamaoka Y, Itoh K, et al. Choledochojejunostomy: Possible risk factor for septic complications after percutaneous hepatic tumor ablation. AJR Am J Roentgenol 2000;174:985-6.         [ Links ]

3. Shibata T, Yamamoto Y, Yamamoto N, Maetani Y, Shibata T, Ikai I, et al. Cholangitis and liver abscess after percutaneous ablation therapy for liver tumors: incidence and risk factors. J Vasc Interv Radiol 2003;14:1535-42.         [ Links ]

4. Wörns MA, Bosslet T, Victor A, Koch S, Hoppe-Lotichius M, Heise M, et al. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scand J Gastroenterol 2012;47:718-28.         [ Links ]

5. Trevisani F, Frigerio M, Santi V, Grignaschi A, Bernardi M. Hepatocellular carcinoma in non-cirrhotic liver: a reappraisal. Dig Liver Dis 2010;42:341-7.         [ Links ]

6. Castroagudín JF, Delgado M, Villanueva A, Bustamante M, Martínez J, Otero E, et al. Safety of percutaneous ethanol injection as neoadjuvant therapy for hepatocellular carcinoma in waiting list liver transplant candidates. Transplant Proc 2005;37:3871-3.         [ Links ]

7. Shiina S, Tagawa K, Niwa Y, Unuma T, Komatsu Y, Yoshiura K, et al. Percutaneous ethanol injection therapy for hepatocellular carcinoma: results in 146 patients. AJR Am J Roentgenol 1993;160:1023-8.         [ Links ]

8. Kotoh K, Sakai H, Sakamoto S, Nakayama S, Satoh M, Morotomi I, et al. The effect of percutaneous ethanol injection therapy on small solitary hepatocellular carcinoma is comparable to that of hepatectomy. Am J Gastroenterol 1994;89:194-8.         [ Links ]

9. Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolondi L, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101-8.         [ Links ]

10. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999;210:655-61.         [ Links ]

11. Okada S, Aoki K, Okazaki N, Nose H, Yoshimori M, Shimada K, et al. Liver abscess after percutaneous ethanol injection (PEI) therapy for hepatocellular carcinoma: A case report. Hepatogastroenterology 1993;40:496-8.         [ Links ]

12. Spies JB, Rosen RJ, Lebowitz AS. Antibiotic prophylaxis in vascular and interventional radiology: a rational approach. Radiology 1988;166:381-7.         [ Links ]

13. Sato S, Mishiro T, Miyake T, Okamoto E, Furuta K, Azumi T, et al. Prophylactic administration of antibiotics unnecessary following ultrasound-guided biopsy and ablation therapy for liver tumors: Open-labeled randomized prospective study. Hepatol Res 2009;39:40-6.         [ Links ]

 

 

Correspondence:
Fernando Macias-García
Gastroenterology Department
Hospital Universitario de Santiago de Compostela
C/ Choupana, s/n
15706 Santiago de Compostela,
A Coruña. Spain
e-mail: fmacgar@yahoo.es

Received: 26-04-2012
Accepted: 29-08-2012

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons